H
eart failure is becoming a major health problem in both developing and developed countries. 1 In Latin America, this problem is aggravated by the presence of almost 11 million persons with Chagas heart disease. 2 Because of intense immigration from endemic areas, transfusion-related infection is now viewed as a potential threat in the United States. 3 Chronic Chagas cardiomyopathy is a model of heart failure that is characterized by persistent diffuse myocarditis, in which a cross-reactive autoimmunity component is responsible for the maintenance of cellular aggression. 4, 5 The heart is affected throughout, and patients may present signs and symptoms of both right and left heart failure, which has important prognostic value. 6 Because of right ventricular compromise, the volume status of patients with Chagas disease heart failure may be difficult to evaluate, leading to potential overuse of diuretics. No specific treatment is available, although recent data indicate that etiologic treatment may offer some benefit. 7, 8 Over the past few years, B-type natriuretic peptide (BNP) analysis has become an important tool in the diagnosis and risk stratification of patients with heart failure. 9, 10 Testing for BNP has been shown to be a cost-effective diagnostic tool in patients with heart failure, a relevant issue in developing countries. 11 BNP is a neurohormone secreted mainly in heart ventricles in response to volume and pressure overload. 12 Because the left ventricle has a higher muscle mass than the right ventricle, most BNP elevations are thought to be due to left ventricle BNP secretion, rather than right ventricle overload.
Only recently, BNP testing has been introduced as a clinical tool in South America. 13 Few reports on evaluation of BNP levels in patients with Chagas disease heart failure have been published, however. The available data indicate that patients with positive serologic results but no heart compromise have normal BNP levels. 14 Another report has indicated that BNP levels are higher in patients with Chagas disease accompanied by apical aneurysm and complex ventricular arrhythmia than in those with apical aneurysm alone. 15 Because Chagas cardiomyopathy appears to affect the entire heart, O r i g i n a l P a P e r The LVEF was obtained via Simpson's rule with the software provided with the equipment by an observer blinded to the clinical status. 17 Quality of life was assessed by the Minnesota Living With Heart Failure Questionnaire, which was administered by the same research nurse to all participants. 18 A 6-minute walking test was performed according to the protocol of the Studies of Left Ventricular Dysfunction (SOLVD). 19, 20 Heart Catheterization. After an 8-hour fast, patients underwent right and left heart catheterization on digital equipment (Model H-5000; Philips Medical Systems, Andover, MA). Right heart catheterization was done by brachial vein dissection, and a Lehman catheter was introduced to measure pressures. Left heart catheterization was performed by brachial artery dissection through which a Sones catheter was introduced and advanced into the aorta and left heart chambers, where the intracavitary pressures were registered and blood samples collected.
Assays. Blood samples were collected after at least a 15-minute rest. A polyethylene Lehman catheter was inserted into the brachial artery and advanced into the thoracic aorta where 10 mL of blood was drawn into chilled tubes containing 1.5 mg/mL 2-natrium-ethylenediamine tetra-acetic acid, kept in ice, and immediately taken to the laboratory. The plasma was separated in a refrigerated centrifuge at 4C, 2000 rpm for 12 minutes, and then stored at -80C until analyzed. Blood samples from the aorta were selected to represent the average concentration of cytokines from the whole body because regional differences in cytokine concentrations may occur throughout the body.
For BNP, 10 mL of blood was collected from a peripheral vein and plasma separated with the same procedure described above for cytokines. It was quantified using a rapid fluorescence immunoassay (Biosite Diagnostics Inc., San Diego, CA). 21, 22 The inflammatory cytokines tumor necrosis factor (TNF)-a, interferon-g, and transforming growth factor-b were measured with commercially available enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN). All tests were done in duplicate and the mean used as the result.
Statistical Analysis. Statistical analysis was done using SPSS 9 software (SPSS Inc., Chicago, IL). All data are 
Results
Baseline Characteristics of the Study Population. Table I and Table II summarize the demographics, treatment medications, and clinical and biochemical assessment parameters of the patients with heart failure (n=28) and the normal volunteers (n=8). As shown, the mean age and body mass index for the heart failure group were similar to those of the control group. All heart failure patients had stable New York Heart Association (NYHA) class I to IV and were on standard 3-drug therapy, including angiotensinconverting enzyme inhibitors (89%) or angiotensin receptor blockers (11%), digoxin (85%), spironolactone (79%), and diuretics (93%). The use of -adrenergic blocking agents in patients with Chagas disease heart failure has not been routinely recommended because of a lack of clinical data in this specific population; therefore, only 5 (18%) of the heart failure patients were taking a b-blocker. There were no significant differences in the baseline heart rate and mean blood pressure level between patients with heart failure and controls. However, the mean LVEF, left ventricle diastolic diameter, and serum sodium level were significantly different in the heart failure patients compared with the control group (P<.001).
Circulating Levels of BNP in
Patients and Controls. The mean BNP levels were significantly higher in patients with heart failure (568±87 pg/ mL) than in controls (7.8±1.9 pg/mL) (P<.0001; Figure 1 ). Even asymptomatic heart failure patients had higher BNP levels (142±60 pg/mL) than did normal controls (P=.006).
Correlations of BNP Levels
With Clinical, Biochemical, and Immunologic Variables. BNP levels correlated with increasing severity of symptoms, as reflected by increasing levels in NYHA functional class (r=0.58; P=.001; Figure 2 ). Patients with systemic congestion, as evidenced by the presence of peripheral edema and/or ascites, had higher BNP levels (872±127 pg/mL) than those who were euvolemic (424±98 pg/mL; P=.012).
The presence of a third heart sound was associated with higher levels of BNP (912±105 vs 358±105 pg/mL; P=.005). Serum sodium level had a significant negative correlation with BNP level (r=-0.66; P<.002). Hyponatremic patients (sodium level<135 mEq/L) had significantly higher levels of BNP (823±142 vs 143±67; P=.002) compared with patients with normal serum sodium levels. Renal function, evaluated by urea levels, had a positive correlation (r=0.51; P=.02) with BNP level. TNF-a was the only measured cytokine that had a positive correlation with BNP level (r=0.46; P=.015; Figure 3) .
The presence of anemia (defined as a hemoglobin level <12 mg/dL) was associated with higher levels of BNP (778±123 for anemic vs 409±96 pg/ mL for non-anemic patients; P=.032; r=-0.50; P=.009). 

Discussion
This observational study investigated BNP levels in patients with heart failure due to Chagas cardiomyopathy. Our study is in accordance with previous observations that indicate that BNP levels correlate with both systolic and diastolic left ventricle dysfunction. [23] [24] [25] Chagas disease heart failure is a model of heart failure that involves both ventricles simultaneously. 26 Our findings extend the conclusions of observational studies in which the measurement of BNP levels was compared between normal individuals and patients with Chagas disease at different stages. 14, 15, 27 After disease severity is accounted for, differences between patients with heart failure and controls were much more significant. We have also demonstrated that even patients with asymptomatic left ventricle dysfunction had higher BNP levels than normal controls. This finding is not common in other forms of heart failure, in which BNP levels are lower in the absence of congestion. 22 We were able to demonstrate that BNP levels correlated with diastolic function. This finding is in accordance with what has been described previously in other forms of heart failure. 23 This is the first study to correlate BNP levels with invasive hemodynamics in Chagas disease heart failure. Both the right and left sides of the heart were studied, and correlations were established with the hemodynamic profile. We were able 
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to demonstrate that BNP levels correlate with both right and left heart parameters of ventricular dysfunction, with similar strength. This is an interesting finding and may represent a distinct characteristic of Chagas disease heart failure. Ischemic and hypertensive models of heart failure affect mainly the left ventricles, so one would expect that, in this setting, right heart correlations become weaker although still present. 28 In Chagas disease heart failure, however, the heart is affected throughout, and the finding of strong correlations of BNP levels with right atrial and pulmonary wedge pressures is emblematic of this unique situation. In fact, recent evidence indicates that BNP levels predict survival better than levels of atrial natriuretic peptide. 29 BNP levels had an inverse relation to blood pressure level, which is expected because hypotension is also a marker of advanced heart failure and is particularly common in Chagas disease. As expected, BNP level was associated with the presence of clinical evidence of ventricular dysfunction and congestion, such as the presence of a third heart sound and systemic congestion. This is in accordance with previous observations in patients with Chagas disease, in whom the BNP level was more accurate in the identification of patients with ventricular dysfunction. 30 The negative correlation of BNP levels with renal function is likely related to worsening heart failure and development of the cardiorenal syndrome rather than to accumulation of BNP due to diminished renal clearance. Serum sodium level had a negative correlation with BNP levels. This is an expected finding because hyponatremia is a well-recognized marker of poor prognosis in heart failure.
An interesting observation relates to the association of anemia with higher levels of BNP. The presence of anemia has been progressively recognized as a marker of worse prognosis in heart failure. 31 A particular strength of our study is that we could correlate BNP levels with immune activation in Chagas disease heart failure ( Figure 3 ). In this particular form of disease, proinflammatory cytokines are up-regulated and are a key element in disease progression. 4 ,32 BNP level correlated with the level of TNF-a, one of the most potent cytokines involved in the pathogenic process of Chagas disease heart failure. This may represent a simple association of 2 independent prognostic variables, but it may also result from common regulatory processes and/or share similar genes. This association may also have therapeutic implications, regarding the development of new therapies targeted to decrease TNF-a levels. 33 BNP may also be used as an indirect predictor of immune activation status.
The finding of an inverse correlation between BNP level and functional capacity is noteworthy and is in accordance with other studies. 34 The 6-minute walking test is a measure of submaximal exercise that correlates with daily activities. This correlation means that we can trust BNP levels to infer exercise capacity, ie, the higher the BNP level, the lower the exercise capacity.
We were unable to establish a correlation between BNP level and quality of life score, as assessed by the Minnesota Living With Heart Failure Questionnaire. This observation indicates that factors other than congestion are responsible for determining the complex nature of quality of life assessments.
Conclusions
We found that BNP levels in patients with Chagas disease heart failure are elevated and are a marker of disease severity that can be used to noninvasively evaluate and better risk stratify patients with this particular form of heart failure. 
